🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Can Yin

Hong Kong University of Science and Technology

ORCID: 0000-0003-1951-9649

Also affiliated with Inner Mongolia University, IQVIA (United Kingdom), Southwest Medical University, Bioscience (China), Zhejiang University, University of Hong Kong

MedicineNeuroscienceBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.900Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

BMJ Medicine(2023)10.1136/bmjmed-2023-000651
Top 29%
0.692DataRank
Top 29%28 citations

Lovedeep Singh Dhingra, Arya Aminorroaya, Kelly Li, Jin Zhou, Faaizah Arshad +42 more

Papers

Driven by 8 papers — median percentile 53. Top paper: “Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM”.

Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

BMJ Medicine(2023)10.1136/bmjmed-2023-000651
Top 29%
0.692DataRank
Top 29%28 citations

Lovedeep Singh Dhingra, Arya Aminorroaya, Kelly Li, Jin Zhou, Faaizah Arshad +42 more

Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic

JAMA Psychiatry(2023)10.1001/jamapsychiatry.2022.4448
N/A
0.564DataRank · unranked
42 citations

Wallis C. Y. Lau, Yi Chai, Carmen Olga Torre, Robert Howard, Kathy Y. Liu +13 more

Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes

Journal of the American College of Cardiology(2024)10.1016/j.jacc.2024.05.069
N/A
0.557DataRank · unranked
40 citations

Arya Aminorroaya, Lovedeep Singh Dhingra, Phyllis Thangaraj, Aline Pedroso Camargos, Fan Bu +49 more

Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study

Diabetes Care(2025)10.2337/dc25-0154
N/A
0.434DataRank · unranked
17 citations

Fan Bu, Benjamin Viernes, Scott L. DuVall, Michael E. Matheny, Katherine Simon +26 more

Next-generation biosensor technologies for Alzheimer’s disease: Innovations in diagnosis, monitoring, and treatment

Ageing Research Reviews(2026)10.1016/j.arr.2025.102954
N/A
0.330DataRank · unranked
8 citations

Xinxin Tang, Juan Zeng, Zhengqin Wang, Jianing Mi, Ying Liang +4 more

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study

medRxiv(2024)10.1101/2024.02.05.24302354
N/A
0.241DataRank · unranked
4 citations

Arya Aminorroaya, Lovedeep Singh Dhingra, Phyllis Thangaraj, Aline Pedroso Camargos, Fan Bu +49 more

Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups: A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM

medRxiv(2022)10.1101/2022.12.27.22283968
Top 65%
0.208DataRank
Top 65%3 citations

Lovedeep Singh Dhingra, Arya Aminorroaya, Kelly Li, Jin Zhou, Faaizah Arshad +42 more

Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DM

medRxiv(2025)10.1101/2025.05.08.25327248
N/A
0.165DataRank · unranked
2 citations

Fan Bu, Clair Blacketer, Anna Ostropolets, Talita Duarte‐Salles, Benjamin Viernes +29 more